Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Merck: Regulatory Update on Cladribine Tablets
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Biologics-induced autoimmune diseases.
Insight into the mechanism of laquinimod action.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Teriflunomide for multiple sclerosis.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
ARESTIN®
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.

Pages